MedPacto, Inc.
11
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
36.4%
4 terminated/withdrawn out of 11 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
Role: collaborator
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Role: lead
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
Role: lead
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
Role: lead
Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Role: lead
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Role: lead
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
Role: lead
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
Role: lead
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
Role: lead
Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects
Role: lead
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
Role: lead
All 11 trials loaded